Skip to main content

CordenPharma buys Vifor sites

CDMO CordenPharma has acquired the finished drug product manufacturing business of Vifor Pharma Group, which is refocusing its manufacturing on nephrology and iron deficiency. This comprises sites at Fribourg and Ettingen in Switzerland, and Lisbon, Portugal. Terms were not disclosed. The deal is expected to close in Q1 2022.

CordenPharma will integrate the new facilities into its existing network of plants and will organise the operations of the three sites under its small molecule platform. It said that it “plans to utilise the existing manufacturing workforce, while continuing to produce and supply Vifor Pharma products”.

CEO Dr Michael Quirmbach noted that the acquired sites have “competent teams with great cultural fit, state-of-the art infrastructure and a strong compliance track record”. Buying them, he added, will enable the firm to close “gaps in our service offering for oral solid dosage drug product manufacturing and increasing our overall capacity”.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.